Table 2 The subgroup analysis in OS of patients with high TMB compared to low TMB
Subgroup | Number of studies | Effects model | Pooled ES | Heterogeneity | ||
|---|---|---|---|---|---|---|
HR [95% CI] | P | I2 | P-Value | |||
Type of therapy | ||||||
 ICIs | 4 | Fixed | 0.72[0.59,0.87] | 0.001 | 0% | 0.419 |
 Non-ICIs | 7 | Random | 1.76[0.97,3.20] | 0.062 | 82% |  < 0.001 |
Breast cancer subtype | ||||||
 HER2 +  | 5 | Random | 1.57[0.65,3.82] | 0.319 | 82.9% |  < 0.001 |
 TNBC | 4 | Random | 0.83[0.35,1.95] | 0.668 | 77.5% | 0.004 |
Sample source | ||||||
 tumor | 6 | Random | 0.74[0.45,1.21] | 0.227 | 73.7% | 0.002 |
 blood | 6 | Random | 2.25[1.09,4.64] | 0.028 | 86.6% |  < 0.001 |
TMB detection method | ||||||
 NGS | 9 | Random | 1.37[0.78,2.39] | 0.271 | 82% |  < 0.001 |
 WES | 1 | - | 0.21[0.06,0.74] | - | - | - |
TMB cutoff value | ||||||
  ≤ 5 Mut/Mb | 7 | Random | 1.81[1.10,2.98] | 0.02 | 79.2% |  < 0.001 |
  > 5 Mut/Mb | 4 | Fixed | 0.72[0.59,0.87] | 0.001 | 0% | 0.419 |